ProfileGDS5678 / 1443851_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 58% 56% 61% 53% 55% 57% 65% 65% 55% 57% 58% 55% 54% 56% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5391758
GSM967853U87-EV human glioblastoma xenograft - Control 23.4159556
GSM967854U87-EV human glioblastoma xenograft - Control 33.6407661
GSM967855U87-EV human glioblastoma xenograft - Control 43.2557753
GSM967856U87-EV human glioblastoma xenograft - Control 53.3112355
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5608457
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0046565
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9109265
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3497755
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4310957
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5071758
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3490455
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3532454
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3938756